Pharmacogenetics of hepatitis C therapy

Annmarie Liapakis¹, Ira Jacobson

Affiliations

Affiliation

¹ Weill Medical College of Cornell University, Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, 1305 York Avenue, 4th Floor, New York, NY, USA.

PMID: 20136353
DOI: 10.2217/pgs.10.25

Comment

Pharmacogenetics of hepatitis C therapy

Annmarie Liapakis et al. Pharmacogenomics. 2010 Feb.

. 2010 Feb;11(2):135-9.

doi: 10.2217/pgs.10.25.

Authors

Annmarie Liapakis¹, Ira Jacobson

Affiliation

¹ Weill Medical College of Cornell University, Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, 1305 York Avenue, 4th Floor, New York, NY, USA.

PMID: 20136353
DOI: 10.2217/pgs.10.25

No abstract available

PubMed Disclaimer

Comment in

Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection?
Liapakis A, Jesudian AB. Liapakis A, et al. Pharmacogenomics. 2012 Sep;13(12):1317-9. doi: 10.2217/pgs.12.111. Pharmacogenomics. 2012. PMID: 22966879 No abstract available.

Comment on

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group. Welzel TM, et al. Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877. Hepatology. 2009. PMID: 19434718 Free PMC article.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Ge D, et al. Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16. Nature. 2009. PMID: 19684573
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Tanaka Y, et al. Nat Genet. 2009 Oct;41(10):1105-9. doi: 10.1038/ng.449. Epub 2009 Sep 13. Nat Genet. 2009. PMID: 19749757
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. Suppiah V, et al. Nat Genet. 2009 Oct;41(10):1100-4. doi: 10.1038/ng.447. Epub 2009 Sep 13. Nat Genet. 2009. PMID: 19749758

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pharmacogenetics of hepatitis C therapy

Affiliation

Pharmacogenetics of hepatitis C therapy

Authors

Affiliation

Comment in

Comment on

Publication types

LinkOut - more resources

Full Text Sources